Verastem Advances KRAS G12D Inhibitor into Phase 2 Trial for Metastatic Colorectal Cancer — Verastem, Inc.

Event summary

Verastem dosed the first patient in its TARGET-D 203 Phase 2 trial for VS-7375, targeting KRAS G12D-mutated metastatic colorectal cancer (mCRC).
VS-7375 is being evaluated as monotherapy and in combination with anti-EGFR therapies cetuximab or panitumumab.
The trial follows encouraging preliminary data from Verastem's Phase 1/2 study, showing anti-tumor activity across multiple KRAS G12D-driven cancers.
Verastem has now initiated all three of its TARGET-D registration-directed Phase 2 trials for pancreatic, colorectal, and lung cancers.

The big picture

Verastem's progression into Phase 2 trials for VS-7375 underscores the growing focus on precision oncology for KRAS-mutated cancers. The KRAS G12D mutation is prevalent in colorectal, pancreatic, and lung cancers, yet remains an unmet medical need with no FDA-approved targeted therapies. Verastem's strategy of developing a best-in-class inhibitor with dual ON/OFF binding could position it as a key player in this space if clinical success continues.

What we're watching

Clinical Efficacy: Whether VS-7375 can demonstrate sustained anti-tumor activity in the Phase 2 trial, particularly in combination with EGFR blockade.
Regulatory Pathway: The pace at which Verastem advances VS-7375 through registration-directed trials and secures Fast Track Designation for additional indications.
Competitive Positioning: How Verastem differentiates VS-7375 in the KRAS G12D inhibitor space, given its dual ON/OFF inhibition mechanism.